197 related articles for article (PubMed ID: 35381938)
21. Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
Chen H; Poon I; Atenafu EG; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):892-901. PubMed ID: 34890753
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
23. Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?
Hingorani M; Stubley H
Oncol Res Treat; 2023; 46(7-8):312-319. PubMed ID: 37331340
[TBL] [Abstract][Full Text] [Related]
24. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer.
Pasalic D; Betancourt-Cuellar SL; Taku N; Ludmir EB; Lu Y; Allen PK; Tang C; Antonoff MB; Fuller CD; Rosenthal DI; Morrison WH; Phan J; Garden AS; Welsh JW; Chang JY; Liao Z; Erasmus JJ; Nguyen QN
Head Neck; 2020 Aug; 42(8):1939-1953. PubMed ID: 32129548
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
29. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
30. Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Nikitas J; Roach M; Robinson C; Bradley J; Huang J; Perkins S; Tsien C; Abraham C
Clin Transl Radiat Oncol; 2020 Mar; 21():32-35. PubMed ID: 31956701
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
[TBL] [Abstract][Full Text] [Related]
32. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
34. Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment.
Apostolidis L; Lang K; Sisic L; Busch E; Ahadova A; Wullenkord R; Nienhüser H; Billeter A; Müller-Stich B; Kloor M; Jaeger D; Haag GM
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1373-1382. PubMed ID: 35441345
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
36. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014.
Stenman M; Sinclair G; Paavola P; Wersäll P; Harmenberg U; Lindskog M
Radiother Oncol; 2018 Jun; 127(3):501-506. PubMed ID: 29754859
[TBL] [Abstract][Full Text] [Related]
37. Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy.
Franceschini D; De Rose F; Franzese C; Comito T; Di Brina L; Radicioni G; Evangelista A; D'Agostino GR; Navarria P; Scorsetti M
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):111-121. PubMed ID: 30630030
[TBL] [Abstract][Full Text] [Related]
38. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
39. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
40. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
